REVER3BAB: AN INNOVATIVE BIOLOGICAL MEDICINE FOR REVERTIRE THE RESISTANCE TO CONVENTIONAL CANCER TREATMENT (Q2035362): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in 2 languages: Changing unique label-description pair) |
|||
| description / en | description / en | ||
Project in Italy | Project Q2035362 in Italy | ||
| description / it | description / it | ||
Progetto in Italia | Progetto Q2035362 in Italia | ||
Revision as of 08:42, 2 November 2020
Project Q2035362 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | REVER3BAB: AN INNOVATIVE BIOLOGICAL MEDICINE FOR REVERTIRE THE RESISTANCE TO CONVENTIONAL CANCER TREATMENT |
Project Q2035362 in Italy |
Statements
423,871.16 Euro
0 references
847,742.32 Euro
0 references
50.0 percent
0 references
13 December 2016
0 references
6 July 2019
0 references
ISTITUTI FISIOTERAPICI OSPITALIERI - IFO
0 references
TAKIS SRL
0 references
ISTITUTO BIOCHIMICO ITALIANO G. LORENZINI
0 references
41°53'35.95"N, 12°28'58.55"E
0 references
REVER3MAB: UN ANTICORPO MONOCLONALE DIRETTO CONTRO LA PROTEINA ERBB3 IN GRADO DI BLOCCARE LA PROLIFERAZIONE DELLE CELLULE TUMORALI IN VITRO E IN VIVO, CON POTENZIALE USO COME AGENTE TERAPEUTICO IN CLINICA. (Italian)
0 references
REVER3BAB: A MONOCLONAL ANTIBODY AGAINST THE ERBB3 PROTEIN CAPABLE OF BLOCKING IN VITRO AND IN VIVO CANCER CELLS, WITH POTENTIAL USE AS A THERAPEUTIC AGENT IN CLINICAL USE. (English)
0 references
Identifiers
F87H18000370007
0 references